GEHC · GE HealthCare Technologies Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $2.12 | H1 2026 | — |
|
|
|||
| Adjusted EBIT margin non-GAAP | 13.8% | H1 2026 | — |
|
|
|||
| Adjusted effective tax rate non-GAAP | 18.6% | H1 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $967M | H1 2026 | — |
|
|
|||
| AIS Organic revenue non-GAAP | $7.18B | H1 2026 | — |
| backlog | $23.9B | Q2 2026 | — |
|
|
|||
| book-to-bill | 1.15 | Q2 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $180M | H1 2026 | — |
|
|
|||
| Organic orders growth non-GAAP | 11.1% | Q2 2026 | — |
|
|
|||
| Organic revenue non-GAAP | $10.1B | H1 2026 | — |
|
|
|||
| Other Organic revenue non-GAAP | $24M | H1 2026 | — |
| PCS Organic revenue non-GAAP | $1.37B | H1 2026 | — |
| PDx Organic revenue non-GAAP | $1.53B | H1 2026 | — |
| Adjusted EBIT* non-GAAP | $691M | Q1 FY2026 | — |
| Adjusted tax expense* non-GAAP | -$120M | Q1 FY2026 | — |
| Share repurchases | 2.8M | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GEHC
this stock
GE HealthCare Technologies Inc.
|
$33.62B | -10.6% | +4.8% | 17.7 | 3.8% |
|
ABT
Abbott Laboratories
|
$203.22B | -8.9% | +5.7% | 32.7 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -6.2% | +11.2% | 34.2 | 1.8% |
|
MDT
Medtronic plc
|
$117.57B | -4.2% | +8.4% | 24.6 | 1.1% |
|
BSX
Boston Scientific Corp
|
$72.26B | -49.5% | +12.5% | 20.2 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GEHC | -1.8% | +2.0% | -4.9% | +7.8% | -10.6% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -1.4% | -3.1% | -17.4% | +5.2% | -23.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.